for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Japan's AnGes begins phase 2/3 clinical trial of DNA-based COVID-19 vaccine

TOKYO (Reuters) - Japanese biotech company AnGes Inc said on Tuesday it had initiated a phase 2/3 clinical trial of its DNA-based COVID-19 vaccine candidate.

The study is taking place at eight facilities in eastern and western Japan involving 500 test subjects, the company said in a statement.

Reporting by Rocky Swift; Editing by Kim Coghill

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up